Business
CB2 Insights Announces Collaboration with FCM Global to Support Medical Cannabis R&D in Colombia
CB2 Insights Announces Collaboration with FCM Global to Support Medical Cannabis R&D in Colombia.
About this update from Skylight Health Group Inc.
[{"type":"text","content":"\n TORONTO, Dec. 03, 2019 (GLOBE NEWSWIRE) -- CB2 Insights (CSE:CBII; OTCQB: CBIIF) (“CB2” or the “Company”), a leading data-driven company focused on bringing real-world evidence-driven from the point-of-care to the medical cannabis community, today announced that it is partnering with Licensed Producer FCM Global (“FCM”), the first Colombian cannabis company to be fully licensed in research, cultivation, extraction, distribution and export.  The partnership will work to create market access and the design of clinical trials to support the deployment of future FCM cannabinoid-based products. FCM owns and operates a 235,800 sq. ft. production facility in La Ceja, Antioquia, as well as an expanded cultivation and biomass production facility of 474 hectares in Tolima. The two companies will look to build a foundation for future clinical trials and product innovation in Colombia. CB2 is one of the only purpose-built technology and CRO services for the maturing global medical cannabis market. The Company will look to blend its clinical operations with technology, analytics clinical research expertise to support FCM with market access, data collection and analysis, and drug discovery. Having three autonomous verticals allow us to put together a comprehensive suite of services and solutions to meet the need of a wide variety of stakeholders. “Research remains the primary gap between new government regulations and patient access – with physicians creating a major barrier due to a lack of understanding of how to prescribe and integrate cannabinoid therapy into traditional treatment programs,” said Prad Sekar, CEO, CB2 Insights.  “In partnership with FCM, we will look to collect real-word evidence data to allow physicians to be come more confident, the industry can be more informed and ultimately creating access for patients incorporating cannabinoid-based therapies into their traditional healthcare. FCM continues to show their leadership by recognizing that traditional healthcare protocols are the key to unlocking the potential of medical cannabis regardless of the jurisdiction. We look forward to laying a framework that places an importance in clinical trials for new products going forward.” Despite having over US$400 million total investments from licensed pro...